Expert Review of Hematology, Volume 10, Issue 7 (2017)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Review of Hematology, Volume 10, Issue 7 (2017)

See all volumes and issues
Vol 17, 2024 Vol 16, 2023 Vol 15, 2022 Vol 14, 2021 Vol 13, 2020 Vol 12, 2019 Vol 11, 2018 Volume 10, 2017 Vol 9, 2016 Vol 8, 2015 Vol 7, 2014 Vol 6, 2013 Vol 5, 2012 Vol 4, 2011 Vol 3, 2010 Vol 2, 2009 Vol 1, 2008
Download citations Download PDFs Download issue

Editorial

Editorial
Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events – is better always good?
Ahmet Emre Eskazan & Deniz Ozmen
Pages: 583-586
Published online: 13 Jun 2017
First Page PreviewforTyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events – is better always good? | Full Text | References | PDF (483.8 KB)
  • 2431 Views
  • 13 CrossRef citations
  • 0Altmetric
Free Access

Special Report

Article
Side effects and potential risk factors of botulinum toxin type A intramuscular injections in knee flexion contractures of hemophiliacs
E. Carlos Rodriguez-Merchan & Hortensia De la Corte-Rodriguez
Pages: 587-594
Published online: 19 Jun 2017
AbstractforSide effects and potential risk factors of botulinum toxin type A intramuscular injections in knee flexion contractures of hemophiliacs | Full Text | References | PDF (692.9 KB)
  • 133 Views
  • 1 CrossRef citations
  • 0Altmetric

Perspective

Article
Therapeutic monitoring of unfractionated heparin – trials and tribulations
Israfil Baluwala, Emmanuel J. Favaloro & Leonardo Pasalic
Pages: 595-605
Published online: 30 Jun 2017
AbstractforTherapeutic monitoring of unfractionated heparin – trials and tribulations | Full Text | References | PDF (855.1 KB)
  • 947 Views
  • 40 CrossRef citations
  • 0Altmetric

Review

Review
Neonatal management and outcome in alloimmune hemolytic disease
Isabelle M. C. Ree, Vivianne E. H. J. Smits-Wintjens, Johanna G. van der Bom, Jeanine M. M. van Klink, Dick Oepkes & Enrico Lopriore
Pages: 607-616
Published online: 05 Jun 2017
AbstractforNeonatal management and outcome in alloimmune hemolytic disease | Full Text | References | PDF (821.9 KB)
  • 20829 Views
  • 58 CrossRef citations
  • 0Altmetric
Open Access
Review
Managing side effects of JAK inhibitors for myelofibrosis in clinical practice
Iram Saeed, Donal McLornan & Claire N. Harrison
Pages: 617-625
Published online: 19 Jun 2017
AbstractforManaging side effects of JAK inhibitors for myelofibrosis in clinical practice | Full Text | References | PDF (726.7 KB)
  • 795 Views
  • 22 CrossRef citations
  • 0Altmetric
Review
Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies
Maria Chiara Finazzi, Federico Lussana, Silvia Salmoiraghi, Orietta Spinelli & Alessandro Rambaldi
Pages: 627-636
Published online: 25 May 2017
AbstractforDetection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies | Full Text | References | PDF (916.3 KB)
  • 235 Views
  • 0 CrossRef citations
  • 0Altmetric
Review
Current options to manage Waldenström’s macroglobulinemia
Giulia Benevolo, Maura Nicolosi, Elisa Santambrogio & Umberto Vitolo
Pages: 637-647
Published online: 19 Jun 2017
AbstractforCurrent options to manage Waldenström’s macroglobulinemia | Full Text | References | PDF (824.3 KB)
  • 498 Views
  • 4 CrossRef citations
  • 0Altmetric
Review
The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity
Wilma Barcellini
Pages: 649-657
Published online: 15 Jun 2017
AbstractforThe relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity | Full Text | References | PDF (925 KB)
  • 427 Views
  • 10 CrossRef citations
  • 0Altmetric
Review
Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?
Ami B. Patel, Brandon W. Wilds & Michael W. Deininger
Pages: 659-674
Published online: 22 May 2017
AbstractforTreating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop? | Full Text | References | PDF (1.4 MB)
  • 679 Views
  • 16 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Early diagnosis of persons with von Willebrand disease using a machine learning algorithm and real-world data
Robert F. Sidonio Jr et al.
Article | Published online: 24 May 2024
Open Access
Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma
Nathalie Javidi-Sharifi et al.
Review Article | Published online: 24 May 2024
Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia
Jorge E. Cortes
Review Article | Published online: 21 May 2024
Open Access
Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
Massimo Martino et al.
Review Article | Published online: 21 May 2024
Open Access
View all latest articles